These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 25254623)

  • 1. Update on the antibiotic resistance crisis.
    Rossolini GM; Arena F; Pecile P; Pollini S
    Curr Opin Pharmacol; 2014 Oct; 18():56-60. PubMed ID: 25254623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview perspective of bacterial resistance.
    Furtado GH; Nicolau DP
    Expert Opin Ther Pat; 2010 Oct; 20(10):1273-6. PubMed ID: 20687782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The growing burden of antimicrobial resistance.
    Hawkey PM
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i1-9. PubMed ID: 18684701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance in antimicrobial photodynamic inactivation of bacteria.
    Maisch T
    Photochem Photobiol Sci; 2015 Aug; 14(8):1518-26. PubMed ID: 26098395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common pathogens in burn wound and changes in their drug sensitivity.
    Rezaei E; Safari H; Naderinasab M; Aliakbarian H
    Burns; 2011 Aug; 37(5):805-7. PubMed ID: 21388742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evolution of bacterial resistance to antibiotics in México, 1973-2013].
    Rodríguez-Noriega E; León-Garnica G; Petersen-Morfín S; Pérez-Gómez HR; González-Díaz E; Morfín-Otero R
    Biomedica; 2014 Apr; 34 Suppl 1():181-90. PubMed ID: 24968050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogens resistant to antibacterial agents.
    Chen LF; Chopra T; Kaye KS
    Infect Dis Clin North Am; 2009 Dec; 23(4):817-45, vii. PubMed ID: 19909886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical distribution and antimicrobial resistance analysis of 754 pathogenic bacteria in diabetic foot infection].
    Shen Q; Lin D; Zhu H; Ge S; Wu W; Pan X; Gu X; Gu X; Shen F
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):889-94. PubMed ID: 24854906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emergence of clinical resistance to tigecycline.
    Sun Y; Cai Y; Liu X; Bai N; Liang B; Wang R
    Int J Antimicrob Agents; 2013 Feb; 41(2):110-6. PubMed ID: 23127485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
    McDonald LC
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redesigning beta-lactams to combat resistance: summary and conclusions.
    Rossolini GM
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():30-3. PubMed ID: 17488374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing bacterial isolates and antibiotic sensitivities of purulent dacryocystitis.
    Briscoe D; Rubowitz A; Assia E
    Orbit; 2005 Mar; 24(1):29-32. PubMed ID: 15764113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future challenges in the development of antimicrobial agents.
    Rennie RP
    Handb Exp Pharmacol; 2012; (211):45-65. PubMed ID: 23090595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibiotic sensitivity of microorganisms, isolated from patients with opportunistic infections].
    Tymchyk OV; Shapiro AV; Vasylenko OH
    Mikrobiol Z; 2005; 67(5):64-8. PubMed ID: 16396113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
    Streit JM; Jones RN; Sader HS; Fritsche TR
    Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria.
    Tang SS; Apisarnthanarak A; Hsu LY
    Adv Drug Deliv Rev; 2014 Nov; 78():3-13. PubMed ID: 25134490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.